Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free HSAQ Stock Alerts

Health Sciences Acquisitions Co. 2 (HSAQ) Competitors

Health Sciences Acquisitions Co. 2 logo
$4.75 +0.51 (+12.03%)
As of 06/29/2026
Compare

HSAQ vs. NSPR, PETV, RVP, TMDIF, and LMNX

Should you buy Health Sciences Acquisitions Co. 2 stock or one of its competitors? MarketBeat compares Health Sciences Acquisitions Co. 2 with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Health Sciences Acquisitions Co. 2 include InspireMD (NSPR), PetVivo (PETV), Retractable Technologies (RVP), Titan Medical (TMDIF), and Defiance Daily Target 2X Long LMND ETF (LMNX). These companies are all part of the "medical" sector.

How does Health Sciences Acquisitions Co. 2 compare to InspireMD?

InspireMD (NYSE:NSPR) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

44.8% of InspireMD shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 29.7% of InspireMD shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InspireMD presently has a consensus price target of $4.50, indicating a potential upside of 542.77%. Given InspireMD's stronger consensus rating and higher probable upside, analysts plainly believe InspireMD is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

InspireMD has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than InspireMD.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InspireMD$10.85M3.02-$19.92M-$0.73N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

In the previous week, InspireMD's average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
InspireMD Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to InspireMD's net margin of -413.96%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat InspireMD's return on equity.

Company Net Margins Return on Equity Return on Assets
InspireMD-413.96% -69.42% -57.68%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Summary

InspireMD beats Health Sciences Acquisitions Co. 2 on 6 of the 11 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to PetVivo?

PetVivo (NASDAQ:PETV) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

24.5% of PetVivo shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, PetVivo had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 6 mentions for PetVivo and 0 mentions for Health Sciences Acquisitions Co. 2. PetVivo's average media sentiment score of 0.17 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that PetVivo is being referred to more favorably in the media.

Company Overall Sentiment
PetVivo Neutral
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat PetVivo's return on equity.

Company Net Margins Return on Equity Return on Assets
PetVivo-902.82% -4,813.07% -281.78%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

PetVivo has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than PetVivo.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PetVivo$1.05M29.25-$10.95M-$0.38N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

Summary

Health Sciences Acquisitions Co. 2 beats PetVivo on 6 of the 10 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Retractable Technologies has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

7.6% of Retractable Technologies shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 59.5% of Retractable Technologies shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Retractable Technologies.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$37.15M0.58-$7.01M-$0.21N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

In the previous week, Retractable Technologies had 1 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 1 mentions for Retractable Technologies and 0 mentions for Health Sciences Acquisitions Co. 2. Retractable Technologies' average media sentiment score of 0.00 equaled Health Sciences Acquisitions Co. 2'saverage media sentiment score.

Company Overall Sentiment
Retractable Technologies Neutral
Health Sciences Acquisitions Co. 2 Neutral

Summary

Health Sciences Acquisitions Co. 2 beats Retractable Technologies on 5 of the 9 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Titan Medical?

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

In the previous week, Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.

Company Overall Sentiment
Health Sciences Acquisitions Co. 2 Neutral
Titan Medical Neutral

Titan Medical has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A
Titan Medical$17.63M1.14$6.95M$0.053.52

Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Titan Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Health Sciences Acquisitions Co. 2N/A N/A -2.38%
Titan Medical N/A -82.31%-51.47%

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market.

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 0.0% of Titan Medical shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 0.0% of Titan Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Health Sciences Acquisitions Co. 2 beats Titan Medical on 4 of the 7 factors compared between the two stocks.

How does Health Sciences Acquisitions Co. 2 compare to Defiance Daily Target 2X Long LMND ETF?

Defiance Daily Target 2X Long LMND ETF (NASDAQ:LMNX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Defiance Daily Target 2X Long LMND ETF has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Defiance Daily Target 2X Long LMND ETF$437.66M0.01$15.17M$0.5132.06
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

In the previous week, Defiance Daily Target 2X Long LMND ETF had 5 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 5 mentions for Defiance Daily Target 2X Long LMND ETF and 0 mentions for Health Sciences Acquisitions Co. 2. Defiance Daily Target 2X Long LMND ETF's average media sentiment score of 0.22 beat Health Sciences Acquisitions Co. 2's score of 0.00 indicating that Defiance Daily Target 2X Long LMND ETF is being referred to more favorably in the media.

Company Overall Sentiment
Defiance Daily Target 2X Long LMND ETF Neutral
Health Sciences Acquisitions Co. 2 Neutral

Defiance Daily Target 2X Long LMND ETF has a net margin of 5.39% compared to Health Sciences Acquisitions Co. 2's net margin of 0.00%. Defiance Daily Target 2X Long LMND ETF's return on equity of 4.66% beat Health Sciences Acquisitions Co. 2's return on equity.

Company Net Margins Return on Equity Return on Assets
Defiance Daily Target 2X Long LMND ETF5.39% 4.66% 2.91%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Defiance Daily Target 2X Long LMND ETF has a beta of 7.56, meaning that its share price is 656% more volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

87.8% of Defiance Daily Target 2X Long LMND ETF shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 6.6% of Defiance Daily Target 2X Long LMND ETF shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Defiance Daily Target 2X Long LMND ETF beats Health Sciences Acquisitions Co. 2 on 8 of the 10 factors compared between the two stocks.

Get Health Sciences Acquisitions Co. 2 News Delivered to You Automatically

Sign up to receive the latest news and ratings for HSAQ and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HSAQ vs. The Competition

Export
MetricHealth Sciences Acquisitions Co. 2Surgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$53.26M$49.99M$7.07B$12.45B
Dividend YieldN/A1.08%2.66%6.16%
P/E RatioN/A19.2927.5124.87
Price / SalesN/A33.28540.69102.84
Price / CashN/A18.8748.5358.59
Price / Book-7.669.0911.016.54
Net Income-$380K-$16.99M$3.57B$336.70M
7 Day Performance17.57%8.54%2.31%2.88%
1 Month Performance21.48%1.23%1.38%0.64%
1 Year Performance77.24%-1.70%36.70%31.34%

Health Sciences Acquisitions Co. 2 Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HSAQ
Health Sciences Acquisitions Co. 2
N/A$4.75
+12.0%		N/A+70.9%$53.26MN/AN/A4
NSPR
InspireMD
3.5209 of 5 stars		$0.70
-0.1%		$4.50
+542.8%		-69.2%$32.79M$10.85MN/A50
PETV
PetVivo
N/A$0.83
+0.6%		N/A+5.0%$30.23M$1.05MN/A20
RVP
Retractable Technologies
N/A$0.72
+4.8%		N/A+12.6%$21.56M$37.15MN/A240
TMDIF
Titan Medical
N/A$0.16
-1.2%		N/A-38.5%$18.44M$17.63MN/A50

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HSAQ) was last updated on 7/1/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel